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Objective: To investigate the efﬁcacy of different electrical stimulation (ES) therapies in pain relief of
patients with knee osteoarthritis (OA).
Method: Electronic databases including MEDLINE, Embase and Cochrane Library were searched through
for randomized controlled trials (RCTs) comparing any ES therapies with control interventions (sham or
blank) or with each other. Bayesian network meta-analysis was used to combine both the direct and
indirect evidence on treatment effectiveness.
Results: 27 trials and six kinds of ES therapies, including high-frequency transcutaneous electrical nerve
stimulation (h-TENS), low-frequency transcutaneous electrical nerve stimulation (l-TENS), neuromus-
cular electrical stimulation (NMES), interferential current (IFC), pulsed electrical stimulation (PES), and
noninvasive interactive neurostimulation (NIN), were included. IFC is the only signiﬁcantly effective
treatment in terms of both pain intensity and change pain score at last follow-up time point when
compared with the control group. Meanwhile, IFC showed the greatest probability of being the best
option among the six treatment methods in pain relief. These estimates barely changed in sensitivity
analysis. However, the evidence of heterogeneity and the limitation in sample size of some studies could
be a potential threat to the validity of results.
Conclusion: IFC seems to be the most promising pain relief treatment for the management of knee OA.
However, evidence was limited due to the heterogeneity and small number of included trials. Although
the recommendation level of the other ES therapies is either uncertain (h-TENS) or not appropriate (l-
TENS, NMES, PES and NIN) for pain relief, it is likely that none of the interventions is dangerous.
Level of evidence: LevelⅡ, systematic review and network meta-analysis of RCTs.
© 2014 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
About 40% of the total population aged over 70 suffers from the
most common form of arthritis-osteoarthritis (OA)1. In the USA,
more than 9,000,000 people are affected by clinically and radio-
graphically conﬁrmed knee OA2. Knee OA is a widespread degen-
erative disease accompanied with great pain, the therapy options
for which are plenty but no enough evidence to support them.G.-h. Lei, Department of Or-
y, #87 Xiangya Road, Chang-
lf of Osteoarthritis Research SocietBecause pain is one of the most important causes for decline of life
quality, the currently available treatments primarily aim to relieve
joint pain for people with knee OA3. For the late-phase patients, so
far the only effective therapy is to replace the knee joint. Combined
with the increasing prevalence of knee OA4, the rapid growth of
knee replacement rate has drawn a high degree of attention to
those effective nonsurgical treatments.
Electrical stimulation (ES) is a noninvasive treatment modality
that involves various stimuli delivered superﬁcially using elec-
trodes placed on the skin5. It has been widely used in many ﬁelds,
such as treatment, rehabilitation, and training purposes. There are
different ES forms, including transcutaneous electrical nerve
stimulation (TENS), neuromuscular electrical stimulation (NMES),
interferential current (IFC), pulsed electrical stimulation (PES),
noninvasive interactive neurostimulation (NIN), etc. Furthermore,y International.
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frequency (50e100 Hz) and low-frequency (2e10 Hz), the option
of which is critical to effectiveness6. During the past few years, a
rapidly growing interest has been observed in testing the treatment
effects, but no consensus has been reached.
Although several systematic reviews and meta-analyses have
been conducted to examine the effects of the three kinds of ES
(including TENS, NMES and PES)7e11, evidence was limited due to
the lack of multiple comparisons of classical meta-analysis.
Bayesian network meta-analysis is a method combining all avail-
able direct and indirect evidences on the relative treatment effects,
enabling a uniﬁed, coherent analysis of all RCTs12e15. With the
accumulation of recent evidence, this study performed a systematic
review and network meta-analysis of randomized controlled trials
(RCTs), which compared all six treatment regimens (high-fre-
quency TENS (h-TENS), low-frequency TENS (l-TENS), NMES, IFC,
PES and NIN) with the control group (sham or no intervention) for
pain relief of patients with knee OA.
Materials and methods
Literature search
The electronic databases of Medline, Embase and Cochrane li-
brary were searched through using the combination of a series of
logic keywords and text words related to OA, interventions of in-
terest and RCT (Appendix 1). The most recent electronic search was
conducted in February 2014. The reference lists of retrieved articles
and reviews were identiﬁed. In addition, the following websites
were searched through to retrieve unpublished and ongoing
studies: Current Controlled Trials (http://www.controlled-trials.
com/), ClinicalTrials.gov (http://www.clinicaltrials.gov/) and the
World Health Organization International Clinical Trials Registry
(http://apps.who.int/trialsearch/Default.aspx) were searched
manually.
Study selection
Firstly, two researchers reviewed all the retrieved abstracts
and full texts independently. If any disagreement was raised, it
would be resolved by discussion and consultation with another
researcher. Those papers meeting the following criteria were
included in the analysis: (1) RCTs; (2) studies concerning patients
with knee OA (3) studies containing at least two of the following
eligible treatments: IFC stimulation, NMES, NINS, PES, TENS (high
frequency or low frequency), and control group (blank or sham);
(4) studies reporting the pain outcome of patients; (5) avail-
ability of full-text; (6) English language. Those trials whose
additional modality (e.g., education or exercise) was unbalanced
between the experimental group and the control group were
excluded.
Quality assessment
Two researchers evaluated the methodological quality of the
included studies separately. The modiﬁed oxford score16,17, a scale
ranged from 0 to 7 according to the descriptions of randomization,
concealment allocation, blinding method and reporting of partici-
pant withdrawals, was used to measure the methodological quality
of all studies.
Outcome measures
The primary goal of this study was to identify the effectiveness
of pain management with different treatments of ES therapy. Themeasures of the relative treatment effect were the degree of
pain intensity and the change pain score at last follow-up time
point. As described by Jüni and colleagues18, the highest score on
the hierarchy of pain scale related outcomes was used if a study
reported multiple pain scales. In order to standardize the pain
outcomes of different studies, all pain scales were converted into a
scale of 0e10 and the pain scores were recalculated19. Only data
from the prior treatment at the last follow-up time point was
extracted. For any study, if the standard deviation (SD) of outcome
was not reported, it would be estimated according to the sample
size, the standard error or the 95% conﬁdence interval (95% CI) or
on the basis of its ﬁgures. Moreover, the SDs of absolute changes
were imputed from baseline in accordance with the details in
the Cochrane Handbook20 when they were not available in any
individual trials. The correlation of r¼ 0.8 between the baseline and
the last follow-up time point was used to estimate the SD for
change from baseline. Lastly, the data of incidence rate of adverse
effects was also extracted in order to evaluate the safety of
interventions.
Statistical analysis
The random effect Bayesian network meta-analysis was used to
compare the relative treatment effect of different treatments of
knee OA. As a major advantage, network meta-analysis allows in-
direct comparisons of interventions among primary trials. In this
study, the effect of pain management was expressed as the stan-
dard mean differences (SMD) among different treatment arms. A
positive value represents a better pain relief effect and a negative
value indicates less pain intensity after treatment.
The random effect Bayesian network meta-analysis was per-
formed using WinBUGS software (version 1.4.3, MRC Biostatistics
Unit, Cambridge, UK), R version 3.0.2 (The R Foundation for Sta-
tistical Computing) and STATA software (version 11.0, StataCorp,
College Station, TX). Network meta-analysis was considered to be
the most comprehensive evidence on multiple treatment compar-
isons15. It combined direct comparisons within trials between two
trials (such as A vs B) and indirect comparisons from trials which
had one common treatment (such as Avs C using trials comparing A
vs B and B vs C)21. The programming codes of random effect models
for multi-arm trials are available at http://www.mtm.uoi.gr/
(Appendix 2). We used Markov Chains Monte Carlo method to
obtain the pooled effect sizes. Three Markov chains run simulta-
neously with different initial values chosen arbitrarily. 50,000
times of simulation were generated for each of the three sets of
initial values. The ﬁrst 10,000 times of simulation were discarded
due to the burn-in period. Pooled effect sizes were reported from
the median of the posterior distribution, and the corresponding
95% credible intervals were applied using the 2.5th and 97.5th
percentiles of the posterior distribution, which is similar to the
conventional 95% CIs. In order to estimate the network inconsis-
tency between indirect and direct estimates in each closed loop, the
absolute difference between indirect and direct treatment effect
estimates were calculated. Loops with the lower CI limit does not
reach zero were considered as statistically signiﬁcant inconsis-
tency22. The ﬁt of model to data was measured by calculating the
posterior mean residual deviance. A model is considered ﬁtting the
data adequately when its mean of the residual deviance is similar to
the number of data points23.
A sensitivity analysis was conducted to examine the impact of
low methodological quality and small sample size on the overall
effect sizes. Meanwhile, in each Markov chain Monte Carlo cycle,
each treatment is ranked according to the estimated effect size.
These probabilities sum to one for each treatment and each rank.
All treatments were ranked based on their effectiveness (ﬁrst
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terior probabilities. Probability values were summarized and re-
ported as the surface under the cumulative ranking (SUCRA)24.
The value of SUCRA is ranged from 0 (worst treatment) to 1 (best
treatment).
Classic pairwise meta-analysis was also performed to evaluate
the heterogeneity across trials and the publication bias by using
STATA software (version 11.0, StataCorp, College Station, TX). The
heterogeneity was tested ﬁrstly by Q statistics (P  0.05 was
considered heterogeneous) and then by I2 statistics,
which measures the percentage of the total variation across
studies (I2  50% was considered heterogeneous). To evaluate the
publication bias, Begg's tests were performed25. Comparison with
a P value less than 0.05 would suggest the existence of publica-
tion bias.
Results
Study selection and characteristics
Figure 1 showed the selection process of included trials. A total
of 1375 records were initially selected from database and website
search. 926 records were identiﬁed after removing duplications.
Then, 792 records were excluded with reasons and 134 full-texts
trials were evaluated for eligibility. Finally, 27 studies26e52 were
included in this research. The details of the included studies are
listed in Table I. The methodological quality assessment (Appendix
3) showed that there were eight low quality studies (score  3), tenFig. 1. Flowchart for the selemedium quality studies (scored 4 or 5), and nine high quality
studies (scored 6 or 7). Data from 20 studies26e43,49,50 which
include eight direct comparisons, and 995 patients with knee OA
was available for network meta-analysis. Figure 2 presented the
network structure of the analyzed comparisons for the primary
outcomes. Results of the studies excluded by the network meta-
analysis were reported in Appendix 4.Pain intensity at last follow-up time point
The results of network meta-analysis about seven treatments
(including the control group) comparing with each other were
reported in Table II. IFC achieved a signiﬁcantly lower pain in-
tensity compared with the control group (SMD: 0.92, 95% CI:
1.72, 0.05), so does h-TENS (SMD: 0.78, 95% CI:
1.34, 0.22). No evidence of inconsistency between the direct
and indirect estimates was observed in this network meta-
analysis (Appendix 5). The evaluation of the goodness of ﬁt for
the models demonstrated adequate ﬁt with a posterior mean
residual deviance of 43.93 (43 data points). The probability dis-
tribution of each treatment was showed in Fig. 3. IFC got the
highest probability (88%) and h-TENS got the second highest
(74%) among all the seven treatments. Four direct comparisons
showed signiﬁcant evidence of heterogeneity (Appendix 6). There
is no publication bias observed among studies except for the
comparison between the high frequency of TENS and the control
group (P ¼ 0.01).ction of included trials.
Table I
Characteristics of included studies
Study Groups Balance* N Age (years) Gender (M/F) Mean BMI Parameters of intervention Pain score Test timez
Itoh
2008
G1: IFC
G2: blank
None 6
6
62e83y 11/21y None 15 min, beat frequency: 122 Hz,
feed frequency: 4 and
4.122 kHz
VAS, WOMAC 0, 1, 2, 3, 4, 5, 10 weeks
Gundog
2012
G1: 40 Hz IFC
G2: 100 Hz IFC
G3: 180 Hz IFC
G4: sham
None 15
15
15
15
59.6
59.6
60.2
60.5
3/12
3/12
3/12
3/12
28.1
29.5
28.7
28.8
20 min  5 times  3 weeks,
strong but comfortable level
VAS, WOMAC 0, 1 month
Elboim-Gabyzon
2013
G1: NMES
G2: blank
Exercise 25
25
68.3
69.4
4/21
4/21
31.4
30.5
45 min  12 times (within 8
weeks), biphasic pulses, 75 Hz
and 250 ms phase duration
VAS 1 week
Palmieri-Smith
2010
G1: NMES
G2: blank
None 16
14
58
56.8
Only females 32.7
32.1
3 times  4 weeks, 50 Hz, duty
cycle ramp up 2 s, 10 s on-50 s
off, intensity adjusted to at least
35% of MVC
WOMAC 5, 16 weeks
Gaines
2012
G1: NMES
G2: blank
Education 20
18
70.8
70.9
3/17
5/13
31.5
31.6
15 min  3 times  12 weeks,
50 Hz, rectangular waveform,
pulsed, ramp up 3 s, 10 s on-
50 s off, intensity for ﬁrst 4
weeks at 10e20% MVC, weeks 5
e8 20e30% MVC, weeks 9e12
30e40% MVC
PPI, PRIT, AIMS2-PS 0, 4, 8, 12, 16 weeks
Talbot
2003
G1: NMES
G2: blank
Education 18
16
70.1
70.8
3/15
4/12
29.5
31.6
15 min  3 times  4 weeks,
50 Hz, rectangular waveform,
pulsed, duty cycle 3 s ramp-up
1.5 ramp-down 10 s one10 s
off, intensity adjusted to 10
e40% of MVC
PRIT 0, 12 weeks
Mizusaki
2013
G1: NMES
G2: blank
Exercise 44
43
60.6x
61.5x
4/46x
10/40x
30.1x
29.7x
40 min  2 times  8 weeks,
50 Hz, rectangular waveform,
pulsed, 10 s one30 s off every
20 min
WOMAC 8 weeks
Selfe
2008
G1: NIN
G2: sham
None 18
19
70.1
70.0
5/13
7/12
29.3
31.7
20e30 min, weeks 1e3: 3
times, weeks 4e6: 2 times,
weeks 7e8: once a week
NRS, WOMAC, SF-36 1, 4, 8, 12 weeks
Fary
2011
G1: PES
G2: sham
None 34
36
70.7
68.9
17/17
20/16
29.4
26.8
Wear the device 7 h daily for 26
weeks, pulsed, asymmetrically
biphasic, exponentially
decreasing waveform with
100 Hz and pulse width of
4 msec
VAS, WOMAC 4, 16, 26 weeks
Garland
2007
G1: PES
G2: sham
None 39
19
64.3
69.9
12/27
8/11
31.3
30.2
Wear the device for 6 h daily for
12 weeks, 100 Hz, negative
pulsed signal
VAS, WOMAC 3 months
Vance
2012
G1: l-TENS
G2: h-TENS
G3: sham
None 25
25
25
55
57
57
11/14
9/16
9/16
36.2
33.6
39.2
40 to 50 min, low: 4 Hz; high:
100 Hz
VAS (rest, TUG, HTS) None
Pietrosimone
2011
G1: h-TENS
G2: sham
G3: blank
Exercise 10
10
11
None 6/6x
4/8x
5/7x
28.6x
29.5x
28.6x
3 times  4 weeks, 150 Hz WOMAC 2, 4 weeks
Pietrosimone
2009
G1: h-TENS
G2: blank
None 10
12
56
54
6/4
5/7
30.6
33.5
45 min, 15 Hz VAS, WOMAC 20, 30, 45 min
Law
2004
G1: l-TENS
G2: h-TENS
G3: mixed TENS
G4: sham
None 13
12
13
10
82.7x
84.3
80
83.2
0/13
0/12
1/12
0/10
25
24.8
26.4
29.2
40 min  5 times  2 weeks,
low: 2 Hz; high: 100 Hz; mixed:
an alternating frequency of 2 Hz
and 100 Hz
VAS None
None None VAS 0, 2 weeks
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Cheing
2003
G1: h-TENS20
G2: h-TENS40
G3: h-TENS60
G4: sham
10
10
10
8
69.2
63.2
63.5
66.1
1/9
1/9
1/9
1/7
20 min (TENS20); 40 min
(TENS40); 60 min (TENS60), 5
times  2 weeks, 100 Hz
Cheing
2002
G1: h-TENS
G2: sham
None 16
16
65.3
64.1
2/14
1/15
None 60 min  5 times  4 weeks,
80 Hz
VAS 0, 4 weeks
Yurtkuran
1999
G1: l-TENS
G2: sham
None 25
25
45e70
45e69
2/23
3/22
None 20 min  5 times  2 weeks,
4 Hz
PPI 0 week
Grimmer
1992
G1: h-TENS
G2: burst TENS
G3: sham
None 20x
20
20
65.6
65.7
68.4
7/13
8/12
8/12
None 30 min, high: 80 Hz; burst:
three Hz trains of seven 80 Hz
pulses
VAS 0 week
Cetin
2008
G2: h-TENS
G4: blank
Exercise, hot pack 20x
20
61.9
61.1
Only females 29.5
27.7
3 times  8 weeks, 20 min, 60
e100 Hz
VAS 0 week
Atamaz
2012a
G1: h-TENS
G2: IFC
G3: sham
Exercise, education 29
27
67
61.9x
62x
61.6x
6/31x
4/27x
4/27x
28.4x
29.8x
28.5x
3 times  3 weeks, TENS:
20 min, 80 Hz; IFC: 20 min,
100 Hz; CSW: 27.12 MHz, input
300 W, output 3.2 W
VAS, WOMAC 1, 3, 6 months
Rosemffet 2004 G1: FES
G2: blank
Exercise 8
10
60y 6/20y 31.49
29.31
30 min  3 times  8 weeks,
amplitude: 0.2 mlsg, 25-Hz,
intensity: 60e80 V
WOMAC 0 week
Defrin
2005
G1: IFC1
G2: IFC2
G3: IFC3
G4: IFC4
G5: placebo
G6: blank
None 11
11
12
11
9
8
68
70
68
68
73
64
None None 20min 12 treatment sessions,
total 4 weeks; intensity: 30%
above (noxious stimulation) or
30% below (innocuous
stimulation) the pain threshold;
IFC1, noxious and unadjusted;
IFC2, noxious and adjusted;
IFC3, innocuous and
unadjusted; IFC4, innocuous
and adjusted
VAS 0 week
Zizic
1995
G1: PES
G2: sham
None 30
22
None None None Daily for 4 weeks; 100 Hz, 6.2
peak volts
VAS 4 weeks, 6 months
Ng
2003
G1: l-TENS
G2: blank
Standard care
and education
8
8
85.9
85.0
1/23y None 20 min  8 sessions, total 2
weeks; 2 Hz
NRS 0, 2 weeks
Adedoyin
2005
G1: h-TENS
G2: IFC
G3: blank
Exercises 15
16
15
55.4
53.2
56.87
5/10
5/11
8/7
30.3
25.99
26.85
20 min  2 sessions  4 weeks;
TENS: 80 Hz, IFC: 80 Hz
VAS 1, 2, 3, 4 weeks
Simith
1983
G1: l-TENS
G2: sham
None 15
15
65
70
5/10
5/10
None 20 min  8 sessions, over 4
weeks; 5e10 Hz
Subjective linear scale
Adedoyin
2002
G2: IFC
G2: sham
Morning treatments
and exercise
15
15
60.0
58.4
10/20y 27.65
28.80
20 min  8 sessions, total 4
weeks. 100 Hz for ﬁrst 15 min,
80 Hz for next 5 min
VAS 0 week
MVC, maximum voluntary contraction; PPI, present pain intensity; PRIT, Pain Rating Index-Total; AIMS2-PS, Arthritis Impact Measurement Scale 2-Pain Subscale; NRS, numeric rating scale; SF-36, Short Form-36; PSW, pulsed
shortwave; W, watt; ms, microsecond; TUG, Time “up & Go” Test; HTS, heat temporal summation; N, number of subjects.
* Usual cares which were balance between groups.
y Only data for the whole trial is available.
z 0 means at the end of the treatment.
x Only data from the baseline is available.
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Fig. 2. Structure of network formed by interventions and their direct comparisons. The
lines between treatment nodes indicate the direct comparisons made within ran-
domized trials. The width of the lines is proportional to the number of trials comparing
each pair of treatments, and the size of each node is proportional to the number of
randomly assigned participants (sample size). Numbers represents numbers of trials
(number of analyzed patients) per comparison.
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Table II showed the outcome of network meta-analysis in terms
of change pain score at last follow-up time point. It indicated that
only the IFC therapy is signiﬁcantly more effective in pain relief
compared to the control group (SMD: 2.06, 95% CI: 1.1e3.19).
Meanwhile, IFC is also signiﬁcantly more effective than NMES
(SMD: 1.68, 95% CI: 0.36e3), h-TENS (SMD: 1.79, 95% CI: 0.66e3.04)
and l-TENS (SMD: 1.81, 95% CI: 0.28e3.28) in pain relief. There is noTable II
network meta-analyses comparison between results of pain intensity (white) and change
credible intervalsevidence of inconsistency between the direct and indirect evi-
dences (Appendix 5). The model provided an adequate ﬁt to the
data, with a posterior mean residual deviance of 45.04 (43 data
points). Figure 4 shows the probability distribution of each treat-
ment being ranked at each of the possible thirteen positions. Ac-
cording to the results of the posterior probability values of rank, it is
found that the IFC therapy is most likely (98%) to be the best
treatment among all treatments. There are signiﬁcant evidence on
the existence of heterogeneity among the six direct comparisons,
and there is no publication bias observed among various
studies (Appendix 6).Sensitivity analysis
Sensitivity analysis was conducted after excluding the trials of
low methodological quality and small sample size (sample size of
an individual group < 15) in pain intensity at last follow-up time
point. A total of 10 trials containing 640 patients were included in
the sensitivity analysis. According to the results of pain intensity at
last follow-up time point (Appendix 7), IFC again achieved signiﬁ-
cant lower pain intensity than the control group, as well as l-TENS.
In addition, h-TENS achieved signiﬁcantly lower pain intensity than
l-TENS, but it is not signiﬁcantly different from the control group. In
terms of pain relief, the results were similar to the overall analysis,
except that IFC achieved signiﬁcantly better effect compared with
PES.Adverse effects
A total of seven trials reported adverse effects in their results.
Three of them claimed no adverse effects related to the NMES, NINS
and TENS treatment, respectively. Three other studies reported
adverse effect of skin rash related to the PES treatment. However,
there was no signiﬁcant difference between the intervention and
the control group in terms of the proportion of participants
affected. One study reported that one patient in the NMES group
exhibited blood pressure spike (Appendix 8).pain score (grey) at last follow-up time point, the data is presented as SMD and 95%
Fig. 3. Rankings for least pain intensity at last follow-up time point. Graph displays distribution of probabilities for each treatment. X-axis represents rank, Y-axis represents
probabilities. Ranking indicates probability that treatments class is ﬁrst “best,” second “best,” etc.
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This network meta-analysis reviewed six kinds of ES modalities
(h-TENS, l-TENS, NMES, IFC, PES and NIN) in pain relief of patients
with knee OA. The results showed that IFC is the only signiﬁcantly
effective treatment in terms of both pain intensity and change painFig. 4. Rankings for effectiveness of change pain score at last follow-up time point. X-axis
bilities for each treatment. Ranking indicates probability that treatments class is ﬁrst “bestscore at last follow-up time point when comparing with the control
group (blank or sham). Meanwhile, IFC is most likely (highest
probability) to be the best treatment option among the six treat-
ment methods in pain relief. These ﬁndings barely changed in
sensitivity analysis.represents rank, Y-axis represents probabilities. Graph displays distribution of proba-
,” second “best,” etc.
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(4,000 Hz) through superﬁcial electrodes placed on the skin, was
developed in the early 1950s for diminishing skin impedance53e55. It
possesses an added advantage of generating a parameter of
amplitude-modulated frequency (AMF), which is a low-frequency
current able to permeate more deeply and has been claimed as the
main analgesic component of IFC55,56. Although IFC has beenwidely
adopted throughout the world57e60, a guidelines (2014)61 developed
by the Osteoarthritis Research Society International (OARSI) recently
did notmention it as an effective therapy. A review published in 2013
covering almost all the rehabilitation interventions for OA suggested
that IFCdidnot demonstrate beneﬁts over the shamcontrol62, but the
evidence was limited because it only included one RCT. Of note, a
Cochrane systematic review conducted in 2009 observed very sig-
niﬁcant effects of IFC on pain relief7, which was consistent with our
results. Compare to the results of single pairwise classical meta-
analysis, the ﬁndings of this study could be more useful in helping
policymakers, service commissioners, and providersmaking choices
among multiple ES therapies63.
For the pain relief measurement, there are two commonly used
options of network meta-analyses published in the British Medical
Journal recently19,64. One calculated the change scores from base-
line in case there were signiﬁcant baseline differences caused by
small sample size of the included studies64; the other one was
based on pain intensity after treatmentwithout clear explanation19.
In addition, pain intensity decreases and change score differences
might disagree. In view of such conditions, both of these two
indices were used in this study to determine whether the results
were consistent. As expected, part of the results were contradic-
tory; for example, h-TENS achieved signiﬁcantly lower pain in-
tensity compared with the control group but did not perform better
in terms of change pain score. Admittedly, except for the possibil-
ities of signiﬁcant baseline differences, like some other network
meta-analysis64, we estimated SD which was not reported in the
original studies. This could partially explain the cause of inconsis-
tency, deserving more attention for subsequent researches.
Similar to IFC, TENS is a form of electroanalgesia based on the
gate control theory of pain perception65, which delivers biphasic
pulsed currents through two electrodes66,67. The previous system-
atic review andmeta-analysis came to totally opposite conclusions:
the meta-analysis showed a signiﬁcant relief in knee OA pain (10),
while the Cochrane systematic review did not7. Based on the
Cochrane systematic review7 and one RCT68 in 2012, the recom-
mendation level of TENS in the guidelines (2014)61 developed by
OARSI was uncertain for knee OA. Although the effect of pain relief
was not consistent between pain intensity and change pain score at
last follow-up time point, this study tends to suggest that h-TENS
ranks the second in terms of the probability of being the best
treatment option among the six methods, because half of the SD
were estimated to calculate the overall change pain score and all of
the baseline pain score differences between different groups were
not signiﬁcant. The other interventions (l-TENS, NMES, PES and
NIN) failed to achieve better effects in pain relief when compared
with the control group in terms of both indices.
Besides the effect of pain relief, the safety issue has also raised a
lot of concerns. Similar to a systematic review and meta-analysis
published in 20138, this study did not ﬁnd any advantage of PES
in pain relief when compared with the control group. However, it is
clear that skin rash is associated with PES no matter in the PES
group or in the sham group due to the use of conducting gel. Even
though Fary et al. reported a much lower rate of adverse skin re-
action when comparing biphasic current with monophasic current
in healthy subjects69, the RCT34 conducted by Fary et al., in 2011
only observed a slight decrease in skin rash in comparisonwith the
two previous RCTs35,48. Fortunately, these incidences of skin rashwere mild without occurrence of systemic reactions. So far, there is
no obvious evidence showing that ES is unsafe except for some skin
reactions in PES.
As far as we know, this is the ﬁrst network meta-analysis of ES
for knee OA, which integrated evidences from both direct and in-
direct comparisons for evaluating the relative effectiveness of pain
relief. In this study, a comprehensive literature search with several
databases and sources was performed to cover as many eligible
trials as possible. Unlike some other network meta-analysis70, the
control group of this study was limited to sham or blank control,
and the additional modality (e.g., education or exercise) was
required to be balanced between groups in order to eliminate the
potential impact of standard care. The differences between
choosing pain intensity or change pain score to measure the effect
of pain relief were also ﬁgured out in this study. This should be
taken into account for further studies.
Nevertheless, the limitations of this study should not be ignored.
Firstly, variations of treatment sessions, treating different doses of
the same ES, and the different ﬁnal follow-up time point might
contribute to the signiﬁcant evidence of heterogeneity. Although
this study suggested that IFC seems to be the most promising pain
relief treatment for the management of knee OA, evidence was
limited due to the heterogeneity and small number of included
trials. Fortunately, no obvious evidence of inconsistency was
observed in this network meta-analysis. Secondly, the low level of
methodological quality and the limitation in sample size of some
studies could be a potential threat to the validity of results. How-
ever, the stability of the results of the sensitivity analyses conﬁrms
that the main ﬁndings of this research are robust and justiﬁed.
Thirdly, this study only focused on the effectiveness of pain relief,
without assessing the function improvement. The reason lies in the
diversity of evaluation indices, which made it difﬁcult to combine
all indices together.
Conclusion
Our ﬁndings indicate that IFC seems to be the most promising
pain relief treatment for the management of knee OA. However,
evidencewas limited due to the heterogeneity and small number of
included trials. Although the recommendation level of the other ES
therapies is either uncertain (h-TENS) or not appropriate (l-TENS,
NMES, PES and NIN) for pain relief, it is likely that none of the in-
terventions is dangerous.
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Appendix 1. Search strategies for MEDLINE, The Cochrane
Library and EMBASE database
Ovid/medline
1. osteoarthriti$.ti,ab,sh.
2. osteoarthro$.ti,ab,sh.
3. osteo?arthritic.ti,ab,sh.
4. gonarthriti$.ti,ab,sh.
5. gonarthro$.ti,ab,sh.
6. coxarthriti$.ti,ab,sh.
7. coxarthro$.ti,ab,sh.
8. arthros$.ti,ab.
9. arthrot$.ti,ab.
10. ((knee$ or hip$ or joint$) adj3 (pain$ or ach$ or
discomfort$)).ti,ab.
11. ((knee$ or hip$ or joint$) adj3 stiff$).ti,ab.
12. OR/1-11
13. exp electric stimulation therapy/
14. exp electric stimulation/
15. exp Electrical Stimulation Therapy/
16. iontophoresis.tw.
17. ((electric$ or electro$) adj (nerve or therapy)).tw.
18. ((electric$ or electro$) adj (stimulation or muscle)).tw.
19. ((electric$ or electro$) adj (function)).tw.
20. (high volt) or pulsed or electrostimulation or
electroanalgezia.tw.
21. (ems or nes or nems or tens or tns or altens).tw.
22. neuromusc$ electric$.tw.
23. ((electric$ or electro$) adj25 current).tw.
24. ((electrical muscle stimulation) or (functional electrical
stimulation) or (high voltage pulsed current) or (neuro-
muscular electrical stimulation) or (transcutaneous nerve
stimulation)).tw.
25. OR/13-24
26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. randomized.ab.
29. placebo.ab,tw.
30. controlled.ti,ab.
31. randomly.ti,ab.
32. trial.ti,ab.
33. groups.ti,ab
34. ((randomized controlled trials) or (random$ allocation) or
(double blind) or (single blind)).tw.
35. ((singl$ or doubl$ or tripl$) and (mask$ or blind$)).tw.
36. OR/26-35
37. 12 AND 25 AND 36
The Cochrane Library
#1. osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonar-
thro* OR coxarthriti* OR coxarthro* OR arthros* OR arthrot*
#2. (knee* OR joint*) near/3 (pain* OR ach* OR discomfort*)
#3. (knee* OR joint*) near/3 stiff*
#4. MeSH descriptor Osteoarthritis explode all trees
#5. #1 or #2 or #3 or #4#6. MeSH descriptor electric stimulation therapy explode all
trees
#7. MeSH descriptor Neuromuscular Electrical Stimulation
explode all trees
#8. MeSH descriptor Functional Electrical Stimulation explode
all trees
#9. (electric* and (nerve or therapy or stimulation or muscle or
function)):kw,ti,ab
#10. ((high volt) or pulsed or electrostimulation or
electroanalgezia):kw,ti,ab
#11. (ems or nes or nems or tens or altens or ics):kw,ti,ab
#12. (electrical muscle stimulation) or (functional electrical
stimulation) or (high voltage pulsed current) or (neuromuscular
electrical stimulation) or (transcutaneous nerve stimulation)
#13. #6 or #7 or #8 or #9 or #10 or #11 or #12
#14. #5 and #13
Ovid/EMBASE
1. osteoarthriti$.ti,ab,sh.
2. osteoarthro$.ti,ab,sh.
3. osteo?arthritic.ti,ab,sh.
4. gonarthriti$.ti,ab,sh.
5. gonarthro$.ti,ab,sh.
6. coxarthriti$.ti,ab,sh.
7. coxarthro$.ti,ab,sh.
8. arthros$.ti,ab.
9. arthrot$.ti,ab.
10. ((knee$ or hip$ or joint$) adj3 (pain$ or ach$ or
discomfort$)).ti,ab.
11. ((knee$ or hip$ or joint$) adj3 stiff$).ti,ab.
12. OR/1-11
13. exp electric stimulation therapy/
14. exp electric stimulation/
15. exp Electrical Stimulation Therapy/
16. iontophoresis.tw.
17. ((electric$ or electro$) adj (nerve or therapy)).tw.
18. ((electric$ or electro$) adj (stimulation or muscle)).tw.
19. ((electric$ or electro$) adj (function)).tw.
20. (high volt) or pulsed or electrostimulation or
electroanalgezia.tw.
21. (ems or nes or nems or tens or tns or altens).tw.
22. neuromusc$ electric$.tw.
23. ((electric$ or electro$) adj25 current).tw.
24. ((electrical muscle stimulation) or (functional electrical
stimulation) or (high voltage pulsed current) or (neuro-
muscular electrical stimulation) or (transcutaneous nerve
stimulation)).tw.
25. OR/13-24
26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. randomized.ab.
29. placebo.ab,tw.
30. controlled.ti,ab.
31. randomly.ti,ab.
32. trial.ti,ab.
33. groups.ti,ab.
34. ((randomized controlled trials) or (random$ allocation) or
(double blind) or (single blind)).tw.
35. ((singl$ or doubl$ or tripl$) and (mask$ or blind$)).tw.
36. OR/26-35
37. 12 AND 25 AND 36
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multi-arm trials
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method
Concealment
allocation
Blinding
method
Follow-up Total
score
Itoh 2008 2 1 0 1 4
Gundog 2012 2 1 2 1 6
Elboim-Gabyzon 2013 2 2 2 1 7
Palmieri-Smith 2010 2 2 2 1 7
Gaines 2012 1 0 0 1 2
Talbot 2003 1 0 0 1 2
Mizusaki 2013 2 2 2 1 7
Selfe 2008 2 2 0 1 5
Fary 2011 2 2 2 1 7
Garland 2007 2 2 2 1 7
Vance 2012 2 2 2 1 7
Pietrosim-one 2011 1 2 2 1 6
Pietrosim-one 2009 1 2 2 1 6
Law 2004 2 0 2 1 5
Cheing 2003 1 0 0 1 2
Cheing 2002 1 0 1 1 3
Yurtkuran 1999 1 0 1 1 3
Grimmer 1992 2 0 2 1 5
Cetin 2008 1 0 2 1 4
Atamaz 2012 2 0 2 1 5
Rosemffet 2004 2 0 0 1 3
Defrin 2005 1 0 0 1 2
Zizic 1995 1 0 0 1 2
Ng 2003 2 0 2 1 5
Adedoyin 2005 1 0 2 1 4
Simith 1983 2 2 0 1 5
Adedoyin 2002 1 0 2 1 4
Loop Pain intensity Pain difference
Inconsistency 95% CI Inconsistency 95% CI
IFC, h-TENS, control 0.263 (0.00, 1.88) 2.142 (0.00, 6.92)
h-TENS, l-TENS, control 0.260 (0.00, 2.68) 0.786 (0.00, 2.99)
Comparison Number of
included
studies
Pain intensity at last
follow-up time point
Chang pain score at
last follow-up time
point
Heterogeneity
(P/I2)
Begg's
test
(P)
Heterogeneity
(P/I2)
Begg's
test
(P)
IFC vs control 3 0.00/93% 1.00 0.00/97% 0.30
IFC vs h-TENS 1 e e e e
NMES vs control 5 0.04/61% 0.81 0.005/73% 0.46
NINS vs control 1 e e e e
PES vs control 2 0.69/0% 1.00 0.04/76% 1.00
h-TENS vs control 9 0.00/72% 0.01 0.00/87% 0.47
h-TENS vs l-TENS 2 0.24/29% 1.00 0.05/74% 1.00
l-TENS vs control 3 0.00/93% 1.00 0.00/94% 1.00Appendix 4. Results of the studies not included in the network m
Study Groups Pain scale Outc
Orig
Rosemffet 2004 G1: FES
G2: blank
WOMAC Med
pain
G1:
G2:
Defrin
2005
G1: IFC1(noxious, unadjusted)
G2: IFC2(noxious, adjusted)
G3: IFC3(innocuous, unadjusted)
G4: IFC4(innocuous, adjusted)
G5: sham
G6: blank
VAS Perc
G1:
G2:
G3:
G4:
G5:
G6:
Zizic
1995
G1: PES
G2: sham
VAS Perc
G1:
G2:
Ng
2003
G1: TENS
G2: blank
NRS Perc
G1:
G2:
Adedoyin
2005
G1: h-TENS
G2: IFC
G3: blank
VAS NR
Simith
1983
G1: l-TENS
G2: sham
Subjective linear scale
(seven points)
Num
G1:
G2:
Jensen
1991
G1: h-TENS
G2: l-TENS
Pain index NR
Adedoyin 2002 G2: IFC
G2: sham
VAS NR
NS: not signiﬁcant, NR: not report.Appendix 5. Assessment of inconsistencyAppendix 6. Results of heterogeneity and publication bias
(Begg's test) according to pairwise meta-analysiseta-analysis
ome of pain
inal data Signiﬁcance of difference
ian (interquartile range) of
intensity after treatment
31.0 (22.7e48.8)
25.0 (13.6e40.0)
NS
ent (%) pain relief from baseline
53.6
64.1
50.0
43.2
14.5
0%
All active treatment groups comparing
with sham, P < 0.05
ent (%) pain relief from baseline
29.42
10.16
P ¼ 0.0365
ent (%) pain relief from baseline
15
NR
NR
NS
ber (%) of patients who had pain relief
7 (46%)
4 (26.7)
NS
NS
P < 0.01
Appendix 8. Details of adverse effects reported in including studies
Study Intervention Adverse effect Number (%) in treatment group Number (%) in control group
Fary 2011 PES Skin rash 6 (18%) 6 (17%)
Garland 2007 PES Skin rash 7 (17.9%) 4 (21.1%)
Zizic 1995 PES Skin rash 7 (24%) 5 (21%)
Imoto 2013 NMES Blood pressure spike 1 (0.02%) 0 (0%)
Appendix 7. Sensitivity analysis between results of pain intensity (white) and change pain score (grey) at last follow-up time point,
the data is presented as SMD and 95% credible intervals
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